An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis
Status: Recruiting
Conditions: Pericarditis
Location:
City/State:
Tucson, Arizona
St. Augustine, Florida
Chicago, Illinois
Park Ridge, Illinois
Owensboro, Kentucky
Houston, Texas
Contact Information:
Name: Ventyx Clinical Trial Contact
Phone Number:
888-411-5176 ext ext 108
Email: [email protected]
Brief Summary
This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Recurrent Pericarditis (RP). Approximately 30 patients will take VTX2735.
The study consists of a 30-day Screening Period (to see if a participant qualifies for the study), a 6-week Open Label Treatment period (a participant receives active Dose A), a 7-week Extension Treatment period (a participant meets criteria for continuing and receives active Dose A) and a 14-day Follow-Up Period.
